PreveCeutical Medical Inc.

C$0.02As of Sun 8 Nov 2026, 12:00 UTC

CSE:PREVHealthcare

Country Canada

PE (Fwd) •••

TSR 9Y CAGR (18.28%)

Div yield —

ROE —

Biotechnology

Beta (5Y) 0.38

PE TTM —

TSR TTM (33.33%)

Mkt cap C$12.76M

ROIC —

SE Grade™

Value

Quality

Moat

Consensus

Reference

$0.02

0.24%

116.21%

Hold 7|3|8|10|7

TTM

FYE 31 Dec CAD

FY2016

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026E

Trend

5Y

10Y

Peers

2.880

Revenue$M

2.271

2.375

2.578

2.707

2.865

3.020

3.164

3.287

3.478

3.687

3.102

5.17%

5.71%

74

12.17

Revenue growth%

28.22

26.01

24.21

26.86

24.67

24.29

25.20

27.11

25.39

28.01

5.84

25.39

25.70

41

26.89

Gross margin%

4.59

4.76

6.25

4.01

2.34

5.34

6.95

5.35

5.08

5.90

13.82

5.35

5.21

52

14.54

Operating margin%

0.40

0.40

0.40

0.40

0.40

2.16

0.82

3.46

1.08

1.42

23.82

1.42

0.61

81

5.80

Net margin%

21.00

21.96

24.10

22.78

25.24

27.52

27.58

25.59

24.05

23.65

4.01

25.59

24.08

30

12.08

P/E ratio (avg)x

22.04

23.67

27.09

30.53

35.65

36.26

38.05

35.46

35.72

37.00

29.35

36.26

35.55

86

31.51

EV/EBITx

7.851

7.630

7.155

6.829

7.280

7.777

8.554

9.317

8.556

8.555

11.22

8.555

7.814

82

11.90

FCF yield (avg)%

10.70

12.44

11.54

8.93

7.88

6.57

5.03

3.48

5.59

7.11

13.19

5.59

7.49

27

5.17

FCF margin%

10.78

8.10

5.67

8.12

9.69

10.39

8.29

7.60

7.14

9.79

6.23

8.29

8.20

24

1.037

FCF / Net incomex

1.600

1.781

1.719

1.658

1.739

1.848

1.756

1.727

1.853

2.102

1.538

1.848

1.747

54

20.85

ROIC%

17.44

17.91

19.73

17.13

16.91

19.71

22.48

22.43

20.87

19.72

2.02

20.87

19.72

85

12.29

Return on equity%

25.55

22.62

20.62

19.52

20.42

21.30

19.97

21.19

18.48

16.67

23.03

19.97

20.52

46

25.08

Return on assets%

4.18

6.74

5.99

3.22

3.59

2.40

2.61

2.95

1.43

1.00

18.83

2.40

3.08

38

—

EPS$

—

—

—

—

—

—

—

—

—

—

—

8.03%

8.70%

—

28.00

EPS growth%

26.32

25.21

24.53

25.16

25.81

23.17

25.26

22.37

22.41

21.80

20.36

22.41

24.85

13

—

Bookvalue per sh$

—

—

—

—

—

0.01

0.01

0.01

0.01

0.01

—

9.20%

8.92%

—

—

FCF per share$

—

—

—

—

—

—

—

—

—

—

—

(1.80%)

(2.09%)

—

—

Dividend per sh$

—

—

—

—

—

—

—

—

—

—

—

2.80%

3.85%

—

6.48

Div yield (avg)%

25.81

26.06

24.89

26.75

27.44

29.81

31.93

31.20

29.97

31.27

12.10

31.20

28.63

84

22.06

Payout ratio%

25.49

26.42

27.46

28.24

26.17

28.82

27.33

26.37

23.85

24.15

17.57

26.37

26.40

58

0.636

Shares (diluted)B

0.710

0.768

0.769

0.794

0.920

1.066

1.031

0.977

0.955

0.912

0.640

(0.19%)

2.00%

66

19.26

Buyback yield%

9.92

8.73

8.87

6.39

6.78

9.30

10.03

10.00

9.64

10.99

16.64

10.00

9.47

16

0.466

D/E ratiox

2.604

2.955

3.411

3.893

3.998

3.976

3.992

4.668

5.199

5.777

0.743

4.668

3.984

76

2.277

Enterprise value$M

2.573

2.407

2.583

2.623

2.540

2.771

2.651

2.627

2.679

2.354

3.582

(1.51%)

(1.83%)

90

1.868

LT debt$M

2.461

2.599

2.687

2.440

2.507

2.461

2.545

2.628

2.528

2.553

1.107

0.37%

0.45%

15

Peers (US$9.034M)

Cap (US$)

PE

Onco-Innovations…

9.800M

—

Lobe Sciences Ltd.

9.614M

—

Lexaria Bioscience…

9.479M

—

CRISM Therapeutics…

9.056M

—

Capital

TTM

5Y

10Y

Leveragex

2.003

0.045

0.044

EBIT/Intx

0.650

0.070

0.072

Own earn%

66.10

149.91

131.18

Sh yield%

25.74

41.20

37.42

Owners

Insiders/Inst%

2.93

33.20

Short interest%

1.81

SBC / revenue%

5.36

Record

10Y

Profitable years

10/10

Revenue growth years

10/10

EPS growth years

10/10

Dividend streakyrs

8

Op margin range%

0–3

$1 testx

0.1

Incr. ROIC%

3

Growth vs revenue

Latest

Trend

10Y CAGR

Rel growth

Revenue

$3.687M

5.71%

1.00×

Cost of revenue

$2.581M

5.71%

1.00×

Operating expenses

$0.569M

5.44%

0.97×